DE602006014821D1 - Ex-vivo-verfahren zur genzuführung - Google Patents

Ex-vivo-verfahren zur genzuführung

Info

Publication number
DE602006014821D1
DE602006014821D1 DE602006014821T DE602006014821T DE602006014821D1 DE 602006014821 D1 DE602006014821 D1 DE 602006014821D1 DE 602006014821 T DE602006014821 T DE 602006014821T DE 602006014821 T DE602006014821 T DE 602006014821T DE 602006014821 D1 DE602006014821 D1 DE 602006014821D1
Authority
DE
Germany
Prior art keywords
generation procedure
vivo generation
particles
magnetic means
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014821T
Other languages
English (en)
Inventor
Jon Dobson
Christopher D Batich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keele University
University of Florida
University of Florida Research Foundation Inc
Original Assignee
Keele University
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keele University, University of Florida, University of Florida Research Foundation Inc filed Critical Keele University
Publication of DE602006014821D1 publication Critical patent/DE602006014821D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006014821T 2005-04-22 2006-04-21 Ex-vivo-verfahren zur genzuführung Active DE602006014821D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0508110.4A GB0508110D0 (en) 2005-04-22 2005-04-22 Gene delivery
PCT/GB2006/001477 WO2006111770A2 (en) 2005-04-22 2006-04-21 Gene delivery

Publications (1)

Publication Number Publication Date
DE602006014821D1 true DE602006014821D1 (de) 2010-07-22

Family

ID=34639915

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014821T Active DE602006014821D1 (de) 2005-04-22 2006-04-21 Ex-vivo-verfahren zur genzuführung

Country Status (11)

Country Link
US (2) US8232102B2 (de)
EP (1) EP1885450B1 (de)
JP (1) JP5167119B2 (de)
CN (1) CN101193681A (de)
AT (1) ATE470477T1 (de)
AU (1) AU2006238697B2 (de)
CA (1) CA2605533A1 (de)
DE (1) DE602006014821D1 (de)
ES (1) ES2345505T3 (de)
GB (1) GB0508110D0 (de)
WO (1) WO2006111770A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
WO2007133801A2 (en) * 2006-05-15 2007-11-22 Dmitri B Kirpotin Magnetic microparticles comprising organic substances
GB0717582D0 (en) * 2007-09-10 2007-10-17 Univ Keele Magnetic transfection device
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9669200B2 (en) 2010-08-06 2017-06-06 Boston Scientific Scimed, Inc. Systems and methods for the treatment of pelvic disorders including magnetic particulates
US9180172B2 (en) 2010-12-15 2015-11-10 Ams Research Corporation Treatment of Peyronies disease
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
CN102172410B (zh) * 2011-01-14 2013-08-07 华南理工大学 用于癌症诊断与治疗的靶向纳米粒传输系统的构建方法
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3800254A1 (de) * 2012-06-08 2021-04-07 Ethris GmbH Pulmonale verabreichung von mrns
CA2881394C (en) 2012-08-13 2024-05-14 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US9951374B2 (en) 2013-02-19 2018-04-24 Wisconsin Alumni Research Foundation Enhanced throughput mineral coatings for optimization of stem cell behavior
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3927425B1 (de) * 2019-02-20 2023-07-12 Sabanci Üniversitesi Magnetisches drehbetätigungssystem
EP4292660A1 (de) * 2022-06-13 2023-12-20 Fortis GmbH System zur verabreichung eines wirkstoffs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652257A (en) * 1985-03-21 1987-03-24 The United States Of America As Represented By The Secretary Of The Navy Magnetically-localizable, polymerized lipid vesicles and method of disrupting same
US6447499B2 (en) * 1995-07-28 2002-09-10 James R. Gray Use of a polarized field to modify the efficacy of a bioactive agent
US6203487B1 (en) * 1997-12-31 2001-03-20 Thomas Jefferson University Use of magnetic particles in the focal delivery of cells
WO2002000870A2 (en) * 2000-06-26 2002-01-03 Christian Plank Method for transfecting cells using a magnetic field
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
AU2003211929A1 (en) 2002-02-12 2003-09-04 Meiryo Technica Corporation, Ltd. Molecule vibrator
WO2004034876A2 (en) 2002-10-15 2004-04-29 Ferx Incorporated Magnetically guided particles for radiative therapies
US8580544B2 (en) 2002-10-16 2013-11-12 Universal Bio Research Co. Ltd. Apparatus for introducing biological material, method of introducing biological material and magnetic support for introducing biological material
US8001977B2 (en) * 2005-04-08 2011-08-23 Nanobiomagnetics, Inc. Device for moving magnetic nanoparticles through tissue
EP1668424A4 (de) 2003-09-12 2009-11-25 Onkor Pharmaceuticals Inc Magnetisch abzielbare partikel mit magnetischen komponenten und biokompatiblen polymeren für die ortsspezifische ablieferung biologisch aktiver wirkstoffe

Also Published As

Publication number Publication date
US8232102B2 (en) 2012-07-31
ATE470477T1 (de) 2010-06-15
ES2345505T3 (es) 2010-09-24
WO2006111770A2 (en) 2006-10-26
WO2006111770A3 (en) 2007-05-18
CN101193681A (zh) 2008-06-04
AU2006238697B2 (en) 2011-12-08
AU2006238697A1 (en) 2006-10-26
US20080286361A1 (en) 2008-11-20
JP2008536907A (ja) 2008-09-11
EP1885450A2 (de) 2008-02-13
JP5167119B2 (ja) 2013-03-21
EP1885450B1 (de) 2010-06-09
CA2605533A1 (en) 2006-10-26
US20120288505A1 (en) 2012-11-15
GB0508110D0 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
DE602006014821D1 (de) Ex-vivo-verfahren zur genzuführung
PH12014502880A1 (en) Lyophilized therapeutic peptibody formulations
TW200806280A (en) Pharmaceutical compositions
HK1136847A1 (en) Targeted integration into the ppp1r12c locus
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
WO2006127768A3 (en) Microscale micropatterned engineered in vitor tissue
MY167579A (en) Glycoconjugation processes and compositions
TW200745109A (en) Pyrrolo-pyridine kinase modulators
PL385388A1 (pl) Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, cząsteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub białka
TR201900670T4 (tr) İnhalasyon için yöntem ve formülasyon.
CO6650414A2 (es) Grupos objetivos de receptro de complemento 2 mejorados
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
MX338980B (es) Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.
WO2009010974A8 (en) Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
WO2010014949A3 (en) Compositions comprising hepatocyte-like cells and uses thereof
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
MY152388A (en) Composition and method for controlling plant diseases
WO2011127244A8 (en) ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.